Lishengpharma(002393)2023-04-26 16:00Financial Performance - The company's revenue for Q1 2023 was CNY 335,604,291, representing a 9.51% increase compared to CNY 306,461,015 in the same period last year[5] - Net profit attributable to shareholders was CNY 46,500,336, marking a 10.84% increase from CNY 41,953,999 in the previous year[5] - Basic and diluted earnings per share were both CNY 0.25, up 8.70% from CNY 0.23 in the same period last year[5] - Total operating revenue for Q1 2023 was CNY 335,604,291, an increase of 9.5% compared to CNY 306,461,015.93 in Q1 2022[21] - Net profit for Q1 2023 reached CNY 46,500,336.40, representing a 10.1% increase from CNY 41,953,999.32 in Q1 2022[22] - The company reported a total comprehensive income of CNY 46,500,336.40 for Q1 2023, compared to CNY 41,953,999.32 in the same period last year[22] Cash Flow and Investments - The net cash flow from operating activities reached CNY 57,529,078, a significant increase of 75.03% compared to CNY 32,867,367 in Q1 2022[5] - Operating cash inflow totaled CNY 279,472,368.80, an increase of 31.43% compared to the previous year[12] - Cash outflow from investment activities amounted to CNY 83,213,283.93, an increase of 526.80% compared to the same period last year, primarily due to the purchase of financial products[14] - Net cash flow from investment activities reached CNY 123,218,552.48, an increase of 1028.14% year-on-year, driven by the redemption and purchase of financial products[14] - Net increase in cash and cash equivalents was CNY 180,747,631.06, reflecting an increase of 822.58% compared to the previous year, mainly due to the redemption of financial products and increased cash receipts from sales[14] Assets and Liabilities - Total assets at the end of the reporting period were CNY 5,359,705,857, reflecting a 1.30% increase from CNY 5,291,039,548 at the end of the previous year[5] - Total current assets at the end of the reporting period amounted to CNY 2,636,640,710.20, slightly up from CNY 2,625,403,269.58 at the beginning of the year[18] - Total liabilities amounted to CNY 945,597,383.38, an increase from CNY 941,660,896.69 at the beginning of the year[19] - The company’s long-term equity investments increased to CNY 76,639,709.29 from CNY 72,501,812.44 at the beginning of the year[18] - The company’s total equity attributable to shareholders increased by 1.49% to CNY 4,414,108,473.96 compared to the end of the previous year[5] Shareholder Information - Total number of common shareholders at the end of the reporting period is 18,544[14] Research and Development - Research and development expenses for Q1 2023 were CNY 23,927,742.21, a decrease from CNY 25,726,028.46 in Q1 2022[21] Other Information - The company did not report any new product launches or significant market expansion strategies during the quarter[27]